Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024 - - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in ...

Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled "Risk Factors", together with the other information in this Annual Report on Form 10-K. If any of the following risks actually occurs (or if any of those listed elsewhere in th ...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Mark Erlander - CEO Jamie Levine - CFO Conference Call Participants Mark Frahm - TD Cowen Joe Catanzaro - Piper Sandler Companies Andy Hsieh - William Blair & Company Operator Welcome to the Cardiff Oncology third-quarter 2023 financial results and corporate update conference call. [Operator Instructions]. As a reminder, this call is being recorded today, No ...

2 Onvansertib's clinical signal of efficacy and tolerability 2. Generate data from the 1* line RAS-mutated mCRC CRDF-004 trial in mid-2024 Preclinical programs indications Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC Generate data from the 1*t line RAS-mutated mCRC CRDF-004 trial in mid-2024 1. – Onvansertib and bevacizumab have independent MOAs reducing tumor vasculature – Data from mCRC study in 135 patients identified resistance mechanisms RAS-mut mCRC Onv ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------|-----------------------------|-------|----------------------------|------------------------------|-------|---------------------|-------|--------------------------------------|-------|------------------------------------------------|-------------------------------------|-------|--------------------------------------| | Balance, January 1, 2023 | Preferred Stock Shares \n61 | $ | Preferre ...

1.00- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------|-------|-------|---------------------------------------|--------------|-----------|-------|---------------------------------|---------------|-------|-----------|-----------------------------------------------|-------|-------|-----------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | robability of Survi©177 | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) | Delaware | 27-2004382 | | --- | --- | | ...

Certain statements in this presentation are | --- | --- | --- | |----------------------------|---------------------------------|-----------------------------------------------------------------------------------------| | | | | | Our Drug: Onvansertib | WHAT Onvansertib has achieved | Robust clinical proof-of-concept results in Ph 1b/2 KRAS-mutated mCRC trial | | Highly selective and well- | | | | tolerated PLK1-inhibitor | WHERE Cardiff Oncology is going | Onvansertib has opportunity to become part of SOC i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) | Delaware | 27-2004382 | | --- | --- | | (State or other jurisdiction of incorporation or organization) | ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction of ...